Why the study?
Determining the right dosage of aspirin for the secondary prevention treatment of atherosclerotic cardiovascular disease remains an unanswered and critical question.
Does aspirin 81 mg daily compared to 325 mg daily reduce the composite of all-cause mortality, hospitalization for nonfatal MI, or hospitalization for nonfatal stroke in patients with established ASCVD?
Population
15 000 patients with established ASCVD in routine clinical practice within PCORnet
Comparison
Aspirin 81 mg daily vs 325 mg daily
Design
Pragmatic, open-label, patient-centered randomized clinical trial
Authors
Loading...
Resolves aspirin dosing uncertainty for ASCVD secondary prevention; delivers pragmatic RCT evidence via distributed network.
Does aspirin 81 mg daily compared to 325 mg daily reduce the composite of all-cause mortality, hospitalization for nonfatal MI, or hospitalization for nonfatal stroke in patients with established ASCVD?
The ADAPTABLE trial is a pragmatic, open-label randomized clinical trial designed to determine the optimal dose of aspirin (81 mg vs 325 mg) for secondary prevention of ASCVD using a distributed research network.
Marquis‐Gravel et al. (2020) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: